LEGN
Legend BiotechCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The primary-source bull case is that CARVYKTI is already commercial at scale: Q4 2025 net trade sales were about $1.9 billion for the year, more than 10,000 patients had been treated, the franchise reached profitability, and management still pointed to company-wide operating profit in 2026 if supply and site expansion keep converting into starts. [#PR-2026-03-10]
Posture
Mixed
Lead driver
Momentum
What changed
3 setup hits (3d) with net bullish as of 2026-06-03.
What can break
CARVYKTI safety remains material, including CRS, neurologic toxicities, HLH/MAS, prolonged cytopenias, enterocolitis, and secondary hematologic malignancies flagged in company materials.
Momentum
91
Value
41
Sentiment
24
Setup hits (3d)
3 · Net Bullish
AI TargetsBase $28.00 · Bull $42.00 · Bear $14.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-30 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Bullish
Target $59.70
Why
Momentum91 · Δ7d -0.3
Value41 · Δ7d +0.1
Sentiment24 · Δ7d +17.6
So what
Balanced signals (Net Bullish). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
91
34% active weight
Current posture
7d trendFlat
Δ7d
-0.3
Δ21d
+0.2
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
24
33% active weight
Current posture
7d trendImproving
Δ7d
+17.6
Δ21d
+8.5
Why this grade
Composite grade C. Momentum 91.3 / Value 41.1 / Sentiment 23.6
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$6.74B
Beta
0.11
Shares Out
369.38M
P/E (TTM) · Derived
-19.4
P/S (TTM)
4.13
P/FCF (TTM) · Derived
-17.79
Rev YoY
+70.0%
EPS YoY
+68.6%
Gross Margin
+60.6%
Op Margin
-21.6%
Net Debt
-$772.15M
Current Ratio
2.86
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology